

NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

Market Update

Sydney Australia Thursday, 29 June 2023: Next Science Limited (ASX: NXS) (**Next Science or Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, is pleased to provide the following update.

In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be **above** US\$5.6m. This compares with reported product sales of US\$4.4m in 1QFY23.

As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (US\$5.2m) and 2HFY22 (US\$6.1m). This is due to the increased investment in sales and marketing that will continue during the establishment phase of our direct sales model for key products.

As noted in the Chair's AGM address on 26 May 2023, monthly sales in the Wound Care DME business surpassed \$1m in April. Operating momentum has continued through the current quarter with ongoing evidence of sales traction in the commercial wound care market.

Approved and authorised for release by the Board of Directors.

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

NEXT SCIENCE®

Forward looking statements

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may” and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.